Equillium Inc.: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Equillium Inc. listata cu simbolul US.EQ ==Descriere companie== Equillium, Inc. (www.quilliumbio.com) is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with high unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, a first-in-class monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially exp...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Equillium, Inc. (www.quilliumbio.com) is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with high unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, a first-in-class monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. | Equillium, Inc. (www.quilliumbio.com) is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with high unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, a first-in-class monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a [[CENTRAL|central]] role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 30 septembrie 2024 17:20
Pagina dedicata companiei Equillium Inc. listata cu simbolul US.EQ
Descriere companie[edit | ]
Equillium, Inc. (www.quilliumbio.com) is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with high unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, a first-in-class monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders.
Grafic actiuni companie[edit | ]